Adult Stem Cell Awareness

July 27, 2009

Man Treated for Heart Failure With Own Cardiac Stem Cells

Filed under: adult stem cell awareness,alternative sources — chelseaz @ 11:16 pm

A team of University of Louisville physicians at Jewish Hospital successfully conduct what is being reported as the world’s first adult cardiac stem cell injection:

After two heart attacks, Michael Jones of Louisville suffered heart failure that made him so weak he could manage only a few football passes now and then with his grandson.

But after becoming one of the world’s first heart patients to get an infusion of cardiac stem cells, Jones said he works out on a treadmill and bike and feels invigorated.

“I hope to have as normal a life as anyone,” “the self-employed painting and remodeling contractor said at a news conference Friday. “I might even start jogging again.”

Jones, 66, received an infusion of his own stem cells through a minimally invasive catheterization procedure on July 17— as part of a clinical trial being conducted by a team of University of Louisville physicians at Jewish Hospital.

The doctors, who announced the trial and started recruiting patients in February, are using adult cardiac stem cells to heal hearts. They said they were infusing the second patient Friday. A similar procedure, involving slightly different cells, was performed last month in California, doctors said.

Read more

This is not the first time a cardiac patient has been treated with stem cells – see: Stem Cells Treat Heart Attack Patient, Adult Stem Cells Better Choice Than Death or Transplant for Heart Failure Patients, Stem Cells Gave Don Ho 15 Extra Months to Perform – so I think the “first time” they’re referring to is the source of the stem cells rather than the procedure itself.


1 Comment »

  1. 1. It’s all complete B.S. of course…as detailed here:

    2. They conveniently left out of the headline that this was “the first FDA approved US located clinical trial”. The US medical media is great at painting US medical achievements as firsts when in reality, they are 6 yrs behind the rest of the world on stem cell treatments.

    3. Don’t believe it? Here’s the story about my friend James Eilert. You will see his remarkable recovery detailed in the (next?) issue of Men’s Journal.

    4. Even with the clarification of #2, someone forget to tell about all those other FDA approved studies underway, like Texas Heart, VAnderbilt, etc.

    5. Let’s not forget the completed clinical trials at Here are just 5 (completed trials) out of 318 when “heart stem cell” is searched:

    ********Stem Cell Mobilization to Treat Chest Pain and Shortness of Breath in Patients With Coronary Artery Disease –

    ********Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion-3-DES –

    ********Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia –

    ********Bone Marrow Stem Cell Mobilisation Therapy for Acute Myocardial Infarction (AMI)(REVIVAL-2) –

    ********The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris –

    ********Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program Participants –

    and this is one of my favorite…
    ********Stem Cell Study for Patients With Heart Disease –

    With more info included here:

    1: Circulation. 2007 Jun 26;115(25):3165-72. Epub 2007 Jun 11.
    Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.

    Losordo DW, Schatz RA, White CJ, Udelson JE, Veereshwarayya V, Durgin M, Poh KK, Weinstein R, Kearney M, Chaudhry M, Burg A, Eaton L, Heyd L, Thorne T, Shturman L, Hoffmeister P, Story K, Zak V, Dowling D, Traverse JH, Olson RE, Flanagan J, Sodano D, Murayama T, Kawamoto A, Kusano KF, Wollins J, Welt F, Shah P, Soukas P, Asahara T, Henry TD.

    Feinberg Cardiovascular Research Institute, and Department of Medicine, Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital, Chicago, IL 60611, USA.

    BACKGROUND: A growing population of patients with coronary artery disease experiences angina that is not amenable to revascularization and is refractory to medical therapy. Preclinical studies have indicated that human CD34+ stem cells induce neovascularization in ischemic myocardium, which enhances perfusion and function. METHODS AND RESULTS: Twenty-four patients (19 men and 5 women aged 48 to 84 years) with Canadian Cardiovascular Society class 3 or 4 angina who were undergoing optimal medical treatment and who were not candidates for mechanical revascularization were enrolled in a double-blind, randomized (3:1), placebo-controlled dose-escalating study. Patients received granulocyte colony-stimulating factor 5 microg x kg(-1) x d(-1) for 5 days with leukapheresis on the fifth day. Selection of CD34+ cells was performed with a Food and Drug Administration-approved device. Electromechanical mapping was performed to identify ischemic but viable regions of myocardium for injection of cells (versus saline). The total dose of cells was distributed in 10 intramyocardial, transendocardial injections. Patients were required to have an implantable cardioverter-defibrillator or to temporarily wear a LifeVest wearable defibrillator. No incidence was observed of myocardial infarction induced by mobilization or intramyocardial injection. The intramyocardial injection of cells or saline did not result in cardiac enzyme elevation, perforation, or pericardial effusion. No incidence of ventricular tachycardia or ventricular fibrillation occurred during the administration of granulocyte colony-stimulating factor or intramyocardial injections. One patient with a history of sudden cardiac death/ventricular tachycardia/ventricular fibrillation had catheter-induced ventricular tachycardia during mapping that required cardioversion. Serious adverse events were evenly distributed. Efficacy parameters including angina frequency, nitroglycerine usage, exercise time, and Canadian Cardiovascular Society class showed trends that favored CD34+ cell-treated patients versus control subjects given placebo. CONCLUSIONS: A randomized trial of intramyocardial injection of autologous CD34+ cells in patients with intractable angina was completed that provides evidence for feasibility, safety, and bioactivity. A larger phase IIb study is currently under way to further evaluate this therapy.

    Publication Types:

    * Clinical Trial, Phase I
    * Clinical Trial, Phase II
    * Comparative Study
    * Randomized Controlled Trial
    * Research Support, N.I.H., Extramural
    * Research Support, Non-U.S. Gov’t

    PMID: 17562958 [PubMed – indexed for MEDLINE]

    Comment by David Granovsky — July 29, 2009 @ 9:59 am | Reply

RSS feed for comments on this post. TrackBack URI

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

Create a free website or blog at

%d bloggers like this: